Antiretroviral Guidelines
US DHHS Guidelines with Australian commentary
Financial Disclosure
Click here for Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents Financial Disclosure (Reporting Period: February 2016 to October 2017)
|
Name |
Entity |
Relationship |
Benefit to Individual |
Benefit to Institution |
|
Rick Varma (chair) |
None |
N/A |
||
|
Andrew Grulich |
Seqirus |
Grant/grants pending |
X |
|
|
Cancer Council NSW |
Grant/grants pending |
X |
||
|
American Foundation for AIDS Research |
Grant/grants pending |
X |
||
|
Gilead |
Educational presentations |
X |
||
|
Merck |
Educational presentations |
X |
||
|
NHMRC |
Travel expenses |
X |
||
|
Cure Cancer Australia |
Advisory Board Member |
X |
||
|
NSW Ministry of Health |
Grants pending |
X |
||
|
ViiV Healthcare |
Educational presentations |
X |
||
|
Advisory Board Member |
X |
|||
|
Arron Sparkes |
None |
N/A |
||
|
Brent Clifton |
None |
N/A |
||
|
Craig Burnett |
None |
N/A |
||
|
Danielle Collins |
None |
N/A |
||
|
David Nolan |
None |
N/A |
||
|
Lewis MacKinnon |
ViiV Healthcare |
Travel expenses |
X |
|
|
Advisory board membership |
X |
|||
|
Educational activities |
X |
|||
|
WA Department of Health |
Educational activities |
X |
||
|
Novartis |
Educational activities |
X |
||
|
Travel expenses |
X |
|||
|
Astra Zeneca |
Educational activities |
X |
||
|
Advisory board consulting |
X |
|||
|
Mark O’Reilly |
ViiV Healthcare |
Advisory board meetings |
X |
|
|
Grant/grants pending |
X |
|||
|
Honoraria |
X |
|||
|
Gilead Sciences |
Advisory board meetings |
X |
||
|
Honoraria |
X |
|||
|
Travel/accommodation expenses |
X |
|||
|
Rupert Handy |
None |
N/A |